Sterilumen patent-pending UV Light sanitizing solution designed to be retrofitted to Bank ATMs to automatically disinfect surfaces on an ATM machine, including a keyboard, touchscreen, credit card reader between uses
MOUNT VERNON, NY / ACCESSWIRE / September 29, 2020 / Applied UV, Inc. (NASDAQ:AUVI) (“Applied UV” or the “Company”), an infection prevention technology company that applies the power of narrow-range ultra violet light (“UVC”) utilizing its patented devices to destroy pathogens safely, thoroughly, and automatically, today announced that its subsidiary, SteriLumen, Inc. (“SteriLumen”), has filed a patent application with the U.S. Patent and Trademark Office (“USPTO”) pertaining to a system to neutralize pathogens on physical surfaces.
The public is confronted on a daily basis with the numerous surfaces that need to be touched during normal uses, including as examples ATMs, vending machines, escalators, and kiosks with interactive screens. As of 2018, there were approximately 470,000 ATMs in the U.S. These surfaces are touched daily by an inordinate number of people that can harbor and transfer pathogens highly associated with illnesses and diseases. E.coli, salmonella and Staphylococcus aureus and, more recently, coronavirus Covid-19 can be found on these commonly used surfaces and can easily spread to those in the general public if untreated, these bacteria and viruses can be transferred easily to cause serious illness.
Max Munn, President of Applied UV, commented, “We strongly believe that the Sterilumen line of UVC devices are powerful and flexible solutions for safely neutralizing serious pathogens commonly found on surfaces that people come in contact with daily. The newly filed utility patent application strengthens our patent portfolio and will help us expand the capabilities and applications of our platform to other business sectors that need to safely and efficiently address the ever-increasing problem posed by pathogens in public spaces.”
As of August 24, 2020, SteriLumen owned seven issued patents and one pending patent application in the United States; owned one patent application to be imminently issued in the European Union and has 6 pending patent applications in China, the Gulf Cooperation Council (GCC), Hong Kong, Japan, South Korea, and Taiwan. The U.S. patent numbers are 9,724,442, 10,039,853, 10,307,504, 10,456,496, 10,463,759 and 10,639,394 issued on August 8, 2017, August 7, 2018, June 4, 2019, October 29, 2019, November 5, 2019 and May 5, 2020, respectively. The issued patents and pending patent applications cover various aspects of the SteriLumen Disinfecting System including, the disinfection system; disinfection system embedded into a fixture generally, and a vanity mirror specifically, and the mechanical components of any such mirror, including hinge mount and programmable controller for regulating UV light.
A provisional patent application offers a patent applicant an option of filing without including a formal patent claim. The aim of a provisional patent application is to establish an early effective filing date, in addition to allowing the patent applicant or a licensee to ascribe the phrase “patent pending” to any product development and methodologies associated with the subject matter. Once converted into a U.S. non-provisional, the utility application will provide composition of matter protection for Sterilumen’s UVC retrofit device designed to disinfect numerous surfaces normally or typically touched by many people, including, but not limited to, ATMs, vending machines, escalators, and kiosks with interactive screens.
About Applied UV
Applied UV is focused on the development and acquisition of technology that address infection prevention in the healthcare, hospitality, commercial and residential markets. Our products utilize disinfection technology that applies the power of UVC to destroy pathogens safely, thoroughly, and automatically. The Company’s SteriLumen technology was tested at an independent laboratory that found the SteriLumen mirror and drain to be greater than 97% and 99.99%, respectively, effective in killing the OC43 human coronavirus, a strain of human coronavirus that is genetically similar to SARS-CoV-2. According to the independent laboratory, it is expected that SARS-CoV-2, the virus that causes COVID-19 will be killed in a similar manner to OC43. The Company has two wholly owned subsidiaries; SteriLumen and Munn Works, LLC (“Munn Works”). SteriLumen develops disinfection devices and technology that combat hospital acquired infections (HAIs). We formed a team to solve and patent a product and process to neutralize pathogens providing a compelling solution for the hospitality space and a solid path to entering the healthcare market. MunnWorks manufactures fine mirrors specifically for the hospitality industry. Our goal, at Munn Works, is to contribute to the creation of what our design industry clients seek: manufacturing extraordinary framed mirrors.
For more information about Applied UV, Inc., and its subsidiaries, please visit the following websites: https://www.applieduvinc.com/; https://sterilumen.com/; and, https://munnworks.com/.
Forward-Looking Statements
The information contained herein may contain “forward‐looking statements.” Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward‐looking statements are based on the Company’s current expectations and assumptions regarding its business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company’s actual results may differ materially from those contemplated by the forward‐looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward‐looking statements. Factors or events that could cause the Company’s actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward‐looking statements to conform these statements to actual results.
Applied UV Investor Relations
TraDigital IR
Kevin McGrath
+1-646-418-7002
kevin@tradigitalir.com
MJ Clyburn
+1-917-327-6847
clyburn@tradigitalir.com
SOURCE: Applied UV, Inc.